Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
2
Dr Hurvitz on Updated PFS Data From the SERENA-6 Trial in Breast Cancer
3
Dana-Farber Announces Groundbreaking Research Collaboration to Improve Quality of Life for Patients With Metastatic Inflammatory Breast Cancer
4
Dr Appleman on Prior Data With SYNC-T Therapy SV-102 in Prostate Cancer
5